Combined computational and intracellular peptide library screening: towards a potent and selective Fra1 inhibitor

Miao Yu1, Lila Ghamsari2, Jim A Rotolo2

  • 1Department of Biology & Biochemistry, University of Bath Claverton Down Bath BA2 7AY UK j.mason@bath.ac.uk +44 (0)1225386867.

RSC Chemical Biology
|August 30, 2021
PubMed

Insights

Researchers developed a new method to find peptide drugs that target Fra1, an important protein in cancer. This approach uses computational screening and intracellular selection to create specific inhibitors, like the peptide Fra1W, which shows high affinity for Fra1.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Activating Protein 1 (AP-1) is a key transcriptional regulator in cancer, with cJun and cFos being well-studied components.
  • The Fra1 homologue is an important, yet less explored, target for cancer therapies.
  • Developing selective inhibitors for AP-1 family members is challenging due to potential off-target interactions.

Purpose of the Study:

  • To develop a novel methodology for designing peptide antagonists selective for the Fra1 protein.
  • To identify a specific inhibitor for Fra1, distinct from its Jun counterparts.
  • To gain insight into rational peptide design for targeting bZIP family proteins.

Main Methods:

  • Utilized the isCAN computational tool to screen over 75 million peptide library members.
  • Employed intracellular Protein-Complementation Assay (PCA) selection to enrich for high-quality binders.
  • Incorporated design strategies to ensure target engagement and selectivity, avoiding homodimerization and off-target interactions.

Main Results:

  • Successfully narrowed down the peptide library by over 99.8% using computational screening.
  • Identified a selective peptide inhibitor, Fra1W, which binds Fra1 with high affinity (917 nM).
  • Demonstrated that Fra1W achieves specificity through a combination of hydrophobic and electrostatic interactions, avoiding significant binding to cJun.

Conclusions:

  • The isCAN and PCA-based approach provides a robust pipeline for generating target-specific peptide inhibitors.
  • The study offers new insights into rational peptide design for selective inhibition of bZIP family proteins.
  • Fra1W represents a promising lead compound for targeting Fra1 in cancer therapy.

Related Concept Videos